Doxepin is a tricyclic antidepressant. It is sold at higher doses for depression and anxiety and, separately, at a very low dose for insomnia characterized by trouble staying asleep. Because doxepin belongs to the tricyclic antidepressant (TCA) drug class, a dedicated TCA immunoassay is designed to find it. When that happens, it is a true positive, not a false positive, because the test is built to detect tricyclics and doxepin is one. The more common question for most readers is different: whether doxepin will show up on the routine drug test their employer or clinic actually runs. For the standard employment screening panel, used across most workplace and pre employment programs, the answer is almost always no, because that panel does not test for tricyclic antidepressants at all.
This article explains the difference between screening and confirmation testing, why doxepin reacts the way it does on a tricyclic immunoassay, which panels include TCA testing and which do not, and what should happen procedurally when a prescribed medication is part of the picture.
Screening immunoassay versus confirmation testing
Almost every urine or oral fluid drug test starts with an immunoassay. An immunoassay uses antibodies that bind to a target drug or drug class and give a rapid presumptive result. Immunoassays are fast and inexpensive, but they are not perfectly specific. Antibodies built to recognize one drug class can sometimes bind to a chemically similar compound, which is how a drug outside the intended target list occasionally produces a positive screen. Because of this limitation, any nonnegative screening result on a regulated or clinically important test is supposed to go to confirmation testing with gas chromatography mass spectrometry (GC MS) or liquid chromatography tandem mass spectrometry (LC MS), methods that identify the exact molecule rather than a class of similarly shaped molecules. The Substance Abuse and Mental Health Services Administration describes this two step model, screen then confirm, along with the role of the Medical Review Officer (MRO) who reviews laboratory results and any prescription documentation before a result is reported as verified positive, negative, or refusal to test.
A dedicated tricyclic antidepressant immunoassay is a different test from the amphetamine, opiate, cocaine, THC, or PCP immunoassays used on standard employment panels. A TCA immunoassay is built specifically to bind tricyclic compounds such as doxepin, amitriptyline, nortriptyline, imipramine, desipramine, clomipramine, protriptyline, and trimipramine. If a person taking doxepin is given a TCA immunoassay, a positive screen is expected and accurate at the immunoassay stage, because doxepin is exactly what that assay looks for. That is a true positive linked to a real tricyclic in the specimen, confirmed at the molecular level by GC MS or LC MS when confirmation is run, not a cross reactivity artifact.
Why the TCA immunoassay itself is not perfectly specific
The TCA immunoassay has a separate, well documented limitation that is worth understanding, because it shows why screening results are never treated as final. Published case research has reported that quetiapine, an atypical antipsychotic that is chemically similar to tricyclic antidepressants, can produce a false positive result on more than one commercial TCA immunoassay, both in overdose and at ordinary therapeutic urine concentrations. A case analysis published in the Journal of Toxicology, Clinical Toxicology tested three separate TCA immunoassays with quetiapine and found that two of the three read positive at clinically relevant concentrations, while the third did not, showing that cross reactivity on this assay class varies by manufacturer. A separate clinical study found that carbamazepine, an anticonvulsant with a three ring structure similar to the tricyclics, interfered with a serum TCA immunoassay in a dose dependent way, while its related compound oxcarbazepine did not meaningfully interfere with either a serum or a urine TCA assay. That study, published in Pediatrics, is a reminder that structurally related but chemically distinct medications, not just tricyclics themselves, can move a TCA immunoassay result. None of this changes the doxepin question directly, since doxepin is a genuine tricyclic rather than a lookalike compound, but it is the reason confirmation testing and MRO review exist for any TCA screen, positive or borderline, before anyone draws a conclusion from the immunoassay alone.
Standard employment panels do not test for tricyclics
Most workplace drug testing programs, including pre employment, random, and post accident testing, use what is generally described as a five panel test or an extended panel that may run from about five to twelve analyte groups. These panels typically cover marijuana metabolites, cocaine metabolites, opioids, amphetamines and methamphetamine, and phencyclidine, with extended versions adding benzodiazepines, barbiturates, methadone, propoxyphene, or MDMA depending on the program. Tricyclic antidepressants are not part of that analyte list. The federally regulated drug testing program that governs DOT covered safety sensitive employees sets out the exact analytes and cutoff concentrations laboratories must test for, and tricyclic antidepressants do not appear anywhere on that list. The cutoff concentration table in 49 CFR 40.85 names marijuana metabolites, cocaine metabolite, codeine and morphine, hydrocodone and hydromorphone, oxycodone and oxymorphone, 6 acetylmorphine, phencyclidine, amphetamine and methamphetamine, and MDMA and MDA as the required analytes, with no tricyclic antidepressant analyte included.
Because of that, someone taking doxepin for insomnia or for depression and anxiety who is given a standard employment panel, including a DOT regulated panel, has essentially no exposure to a doxepin related result at all. The panel is not looking for tricyclics in the first place, so there is nothing for doxepin to trigger. A TCA specific immunoassay only comes into play in settings that order it on purpose, most often hospital or emergency department toxicology panels, pain management or medication assisted treatment (MAT) program monitoring, or a clinical overdose workup, not a routine pre employment or random workplace screen.
Doxepin and its controlled substance status
Doxepin is approved in a higher dose oral capsule form for major depressive disorder and, in a separate low dose tablet form, for insomnia characterized by difficulty staying asleep. The low dose insomnia labeling on DailyMed states plainly that doxepin is not a controlled substance and is not associated with abuse potential in the studies reviewed by the manufacturer. The higher dose depression labeling confirms the same tricyclic antidepressant classification. That matters for the drug testing question because it means doxepin sits outside the controlled substance and drug abuse monitoring frameworks that drive most routine screening decisions. It is prescribed, legitimate, and not a target of concern for employment screening programs, which is a separate point from whether it happens to belong to the same chemical family as drugs that a dedicated clinical TCA immunoassay is built to catch.
Tricyclic antidepressants and the screens they can affect
| Medication | Dedicated TCA immunoassay (clinical or MAT setting) | Standard employment 5 to 12 panel | Federally regulated DOT panel, 49 CFR part 40 |
|---|---|---|---|
| Doxepin | Detected, true target | Not included | Not included |
| Amitriptyline | Detected, true target | Not included | Not included |
| Nortriptyline | Detected, true target | Not included | Not included |
| Imipramine | Detected, true target | Not included | Not included |
| Desipramine | Detected, true target | Not included | Not included |
| Clomipramine | Detected, true target | Not included | Not included |
| Protriptyline | Detected, true target | Not included | Not included |
| Trimipramine | Detected, true target | Not included | Not included |
Every drug on this list belongs to the tricyclic chemical family, so every one of them is an intended, true target of a dedicated TCA immunoassay rather than a false positive source. None of them appear on a standard employment panel or on the federally regulated DOT analyte list, so none of them are expected to affect a routine workplace screening result.
What should happen when a prescription is involved
If a person is ever given a clinical TCA screen while taking doxepin or another tricyclic, the correct next step is the same process used for any legitimate prescription that overlaps with a tested drug class. The laboratory should move a nonnegative immunoassay result to GC MS or LC MS confirmation rather than report a presumptive screen as final. A Medical Review Officer, a licensed physician trained in the interpretation of drug test results, should review the confirmed result together with prescription documentation before any result is reported to an employer or treatment program as verified. SAMHSA's federal drug free workplace program resources describe this MRO review step, along with the certified laboratory and medical review process that federal workplace testing programs rely on. A person taking doxepin should keep a copy of the prescription or a note from the prescribing clinician on hand so that documentation is available immediately if a clinical or safety sensitive testing situation requires it. This article does not offer medical advice about dosing, starting, or stopping doxepin, and any question about the medication itself belongs with the prescribing clinician.
Frequently asked questions
Does doxepin cause a false positive on a drug test?
Not in the usual sense of that phrase. Doxepin is a genuine tricyclic antidepressant, so a dedicated TCA immunoassay that flags it is working correctly and finding a real tricyclic compound, which is a true positive rather than a false positive. Doxepin does not appear on standard employment drug test panels at all.
Will doxepin show up on a standard 5 panel or 10 panel employment drug test?
No. Standard employment panels, including the federally regulated DOT panel under 49 CFR part 40, test for marijuana, cocaine, opioids, amphetamines, and phencyclidine, with some extended panels adding benzodiazepines or other classes. Tricyclic antidepressants are not part of that analyte list, so doxepin has nothing to trigger on a routine workplace test.
Why would doxepin test positive on a tricyclic antidepressant immunoassay?
Because the TCA immunoassay is built specifically to detect tricyclic antidepressants, and doxepin is a tricyclic antidepressant. A positive result on that specific test reflects the drug it was designed to find, not an error or cross reactivity.
Can other medications cause a false positive tricyclic result instead of doxepin?
Published research has reported that quetiapine and, at higher levels, carbamazepine can interfere with TCA immunoassays and produce a false positive tricyclic result. That interference comes from those specific medications, not from doxepin, and it is one more reason any TCA immunoassay result should go through confirmation testing before it is treated as final.
What should happen if a clinical TCA screen comes back positive for someone taking doxepin?
The laboratory should confirm the screening result with GC MS or LC MS, and a Medical Review Officer should review the confirmed result along with the person's prescription documentation before it is reported as a verified result.
Is doxepin a controlled substance?
No. Doxepin's own prescribing information states that it is not a controlled substance and is not associated with abuse potential in the studies the manufacturer reviewed.
Related reading
- Does Amitriptyline Show Up on a Drug Test? Tricyclics and Panel Screens
- How to Choose a Drug Test Panel: 5, 10, 12 or More for Your Program
Employers and clinics building or restocking a screening program can review drug test cups sized for the panel their program actually needs.
This article is general information about drug testing science and procedure, not medical or legal advice. Anyone with questions about a specific medication, dose, or test result should talk to a prescribing clinician, a Medical Review Officer, or qualified legal counsel.
